PRX302 is designed to provide long-term relief of BPH symptoms, such as restricted urinary flow from enlarged prostate, without causing sexual dysfunction or sacrificing quality of life.
PRX302 is highly targeted to prostate tissue and the therapy is designed to be non-systemic. It is delivered directly to the encapsulated prostate via localized injection. Further, PRX302 has been engineered to be selectively activated by enzymatically active Prostate Specific Antigen (PSA) which is present only in prostate tissue. Once activated, PRX302 forms disruptive pores in the membranes of prostate cells resulting in selective cell death, thus creating a highly targeted, localized approach to killing prostate cells constricting the urethra.